Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients

To explore the efficacy and toxicity of stereotactic body radiation therapy (SBRT) in high-risk prostate cancer (HRPCa) in a consortium of 7 institutional phase 2 trials and prospective registries. Individual patient data were pooled for 344 patients with a minimum follow-up of 24 months. Biochemica...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of radiation oncology, biology, physics Vol. 110; no. 3; pp. 731 - 737
Main Authors:	van Dams, Ritchell, Jiang, Naomi Y., Fuller, Donald B., Loblaw, Andrew, Jiang, Tommy, Katz, Alan J., Collins, Sean P., Aghdam, Nima, Suy, Simeng, Stephans, Kevin L., Yuan, Ye, Nickols, Nicholas G., Murthy, Vedang, Telkhade, Tejshri P., Kupelian, Patrick A., Steinberg, Michael L., Romero, Tahmineh, Kishan, Amar U.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01-07-2021
Subjects:	Aged Aged, 80 and over Androgen Antagonists - therapeutic use CARCINOMAS Clinical Trials, Phase II as Topic Disease-Free Survival Follow-Up Studies Gastrointestinal Tract - radiation effects HEALTH HAZARDS Humans Lymphatic Irradiation Male Middle Aged PATIENTS Proportional Hazards Models Prospective Studies PROSTATE Prostate-Specific Antigen - blood Prostatic Neoplasms - pathology Prostatic Neoplasms - radiotherapy Prostatic Neoplasms - surgery RADIOLOGY AND NUCLEAR MEDICINE Radiosurgery - adverse effects Radiosurgery - methods RADIOTHERAPY Radiotherapy Dosage Registries TOXICITY Urogenital System - radiation effects
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	To explore the efficacy and toxicity of stereotactic body radiation therapy (SBRT) in high-risk prostate cancer (HRPCa) in a consortium of 7 institutional phase 2 trials and prospective registries. Individual patient data were pooled for 344 patients with a minimum follow-up of 24 months. Biochemical recurrence-free survival (BCRFS) and distant metastasis-free survival (DMFS) were estimated using a Kaplan-Meier framework. Fine and Gray competing risk and Cox proportional hazards regression models were developed to assess the association between time to BCR and time to distant metastasis and prespecified variables of interest. Logistic regression models were developed to evaluate associations between acute and late grade ≥2 genitourinary and gastrointestinal and the following a priori–specified variables: age, dose per fraction, ADT use, and nodal radiation therapy. Median follow-up was 49.5 months. Seventy-two percent of patients received ADT, with a median duration of 9 months, and 19% received elective nodal radiation therapy. Estimated 4-year BCRFS and DMFS rates were 81.7% (95% CI, 77.2%-86.5%) and 89.1% (95% CI, 85.3%-93.1%). The crude incidences of late grade ≥3 genitourinary and gastrointestinal toxicity were 2.3% and 0.9%. These data support a favorable toxicity and efficacy profile for SBRT for HRPCa. Further prospective studies are needed to evaluate the optimal dose and target volume in the context of SBRT for HRPCa.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
ISSN:	0360-3016 1879-355X 1879-355X
DOI:	10.1016/j.ijrobp.2021.01.016